Sign In
Buy GRTX
$0.100
-0.0010 (-0.99%)
At Close: Jun 03, 2026
GRTX Stock Alert: Halper Sadeh LLC is Investigating Whether Galera Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
02:14pm, Tuesday, 14'th Apr 2026
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Galera Therapeutics, Inc. (OTC: GRTX) and Obsidian Therapeutics, Inc. Upon closing of the prop
Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
02:08pm, Tuesday, 14'th Apr 2026
CAMBRIDGE, Mass. and MALVERN, Pa., April 14, 2026 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS in
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Galera Therapeutics, Inc. (OTCMKTS: GRTX)
10:57am, Tuesday, 14'th Apr 2026
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholde
Obsidian Therapeutics and Galera Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement
08:54am, Tuesday, 14'th Apr 2026
CAMBRIDGE, Mass. & MALVERN, Pa.--(BUSINESS WIRE)--Galera Therapeutics, Inc. (“Galera”) (OTC: GRTX), a clinical-stage biopharmaceutical company focused on advancing a pan-NOS inhibitor through clin
Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
03:19am, Monday, 16'th Feb 2026
Risk and Volatility Galera Therapeutics has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Comparatively, Athersys has a beta of -0.9, indicating that its share
Critical Review: Galera Therapeutics (NASDAQ:GRTX) versus China Pharma (NYSE:CPHI)
05:08am, Saturday, 27'th Dec 2025
Earnings and Valuation This table compares China Pharma and Galera Therapeutics"s top-line revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Pric
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million
07:00am, Wednesday, 22'nd Oct 2025
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agr
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
07:00am, Tuesday, 31'st Dec 2024
Galera's development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Galera Announces Board Approval of Complete Liquidation and Dissolution
07:00am, Wednesday, 14'th Aug 2024
MALVERN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company historically focused on developing a pipeline of novel, proprietary
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
07:00am, Monday, 13'th May 2024
MALVERN, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics
Galera Adopts Limited Duration Stockholder Rights Agreement
07:00am, Friday, 03'rd May 2024
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the p
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
07:00am, Thursday, 28'th Mar 2024
Company continues to evaluate strategic options to maximize shareholder value Company continues to evaluate strategic options to maximize shareholder value
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
07:00am, Tuesday, 14'th Nov 2023
FDA confirms need for new trial for avasopasem; GRECO trials with rucosopasem to be discontinued Company evaluating potential strategic options to optimize shareholder value MALVERN, Pa., Nov. 14, 202
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
07:00am, Tuesday, 31'st Oct 2023
FDA confirms need for new trial for avasopasem for severe oral mucositis (SOM) GRECO-2 trial did not pass futility analysis; Company will discontinue both GRECO trials Company reviewing potential stra
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
07:00am, Monday, 18'th Sep 2023
MALVERN, Pa., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, pro
